tradingkey.logo

Amneal Pharmaceuticals Inc

AMRX

7.840USD

+0.010+0.13%
Horário de mercado ETCotações atrasadas em 15 min
2.46BValor de mercado
PerdaP/L TTM

Amneal Pharmaceuticals Inc

7.840

+0.010+0.13%
Mais detalhes de Amneal Pharmaceuticals Inc Empresa
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Generics segment includes a retail and institutional portfolio of over 270 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Informações da empresa
Código da empresaAMRX
Nome da EmpresaAmneal Pharmaceuticals Inc
Data de listagemNov 18, 2009
CEOMr. Chintu Patel
Número de funcionários8100
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 18
Endereço400 Crossing Boulevard, 3rd Floor
CidadeBRIDGEWATER
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal08807
Telefone19089473120
Sitehttps://amneal.com/
Código da empresaAMRX
Data de listagemNov 18, 2009
CEOMr. Chintu Patel
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
+1.39%
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-8.60%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+32.21%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
433.93K
-10.17%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+16.38%
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+75.39%
Mr. Chirag Patel
Mr. Chirag Patel
President, Co-Chief Executive Officer, Co-Founder, Director
President, Co-Chief Executive Officer, Co-Founder, Director
--
--
Mr. Ted Nark
Mr. Ted Nark
Independent Director
Independent Director
--
--
Mr. Paul M. Meister
Mr. Paul M. Meister
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. John J. Kiely
Mr. John J. Kiely
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
+1.39%
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-8.60%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+32.21%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
433.93K
-10.17%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+16.38%
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+75.39%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Oral solid
178.95M
25.73%
Distribution
104.89M
15.08%
Central Nervous System
67.61M
9.72%
Other dosage forms
56.42M
8.11%
Government label
50.14M
7.21%
Other
237.40M
34.14%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Oral solid
178.95M
25.73%
Distribution
104.89M
15.08%
Central Nervous System
67.61M
9.72%
Other dosage forms
56.42M
8.11%
Government label
50.14M
7.21%
Other
237.40M
34.14%
Distribuição de ações
Atualizado em: qui, 22 de mai
Atualizado em: qui, 22 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Patel (Tushar Bhikhubhai)
15.50%
Patel (Chintu)
8.17%
Patel (Dipan)
7.60%
Patel (Chirag K)
7.06%
Akram (Mahesh)
6.56%
Other
55.10%
Investidores
Investidores
Proporção
Patel (Tushar Bhikhubhai)
15.50%
Patel (Chintu)
8.17%
Patel (Dipan)
7.60%
Patel (Chirag K)
7.06%
Akram (Mahesh)
6.56%
Other
55.10%
Tipos de investidores
Investidores
Proporção
Individual Investor
46.67%
Investment Advisor
16.20%
Hedge Fund
11.70%
Investment Advisor/Hedge Fund
10.50%
Private Equity
3.93%
Research Firm
0.97%
Pension Fund
0.26%
Bank and Trust
0.17%
Venture Capital
0.03%
Other
9.56%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
429
283.55M
90.47%
-32.20M
2025Q1
437
285.44M
91.08%
-30.39M
2024Q4
413
285.94M
92.29%
-32.70M
2024Q3
398
304.85M
98.50%
-8.45M
2024Q2
391
304.30M
98.56%
+52.65M
2024Q1
375
272.60M
88.40%
+17.73M
2023Q4
366
275.21M
90.82%
+129.07M
2023Q3
354
120.75M
78.38%
-3.68M
2023Q2
353
115.91M
75.59%
-7.89M
2023Q1
359
114.33M
74.58%
-11.39M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Patel (Tushar Bhikhubhai)
48.58M
15.5%
-5.00M
-9.33%
Mar 14, 2025
Patel (Chintu)
25.62M
8.17%
+351.47K
+1.39%
Mar 14, 2025
Patel (Dipan)
23.83M
7.6%
--
--
Mar 14, 2025
Patel (Chirag K)
22.13M
7.06%
+345.41K
+1.59%
Mar 14, 2025
Akram (Mahesh)
20.56M
6.56%
-6.30M
-23.45%
Mar 31, 2025
The Vanguard Group, Inc.
15.71M
5.01%
+920.76K
+6.23%
Mar 31, 2025
TPG Capital, L.P.
12.33M
3.93%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
11.14M
3.55%
-80.92K
-0.72%
Mar 31, 2025
Rubric Capital Management LP
10.74M
3.43%
+14.20K
+0.13%
Mar 31, 2025
Citadel Advisors LLC
7.49M
2.39%
-1.49M
-16.58%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Invesco Pharmaceuticals ETF
3%
SPDR S&P Pharmaceuticals ETF
2.22%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.57%
AltShares Event-Driven ETF
1.53%
First Trust NASDAQ Pharmaceuticals ETF
0.87%
iShares U.S. Pharmaceuticals ETF
0.61%
First Trust Small Cap Growth AlphaDEX Fund
0.53%
First Trust Small Cap Core Alphadex Fund
0.29%
Invesco Nasdaq Biotechnology ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.28%
Ver Mais
Invesco Pharmaceuticals ETF
Proporção3%
SPDR S&P Pharmaceuticals ETF
Proporção2.22%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.57%
AltShares Event-Driven ETF
Proporção1.53%
First Trust NASDAQ Pharmaceuticals ETF
Proporção0.87%
iShares U.S. Pharmaceuticals ETF
Proporção0.61%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.53%
First Trust Small Cap Core Alphadex Fund
Proporção0.29%
Invesco Nasdaq Biotechnology ETF
Proporção0.28%
ProShares Ultra Nasdaq Biotechnology
Proporção0.28%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI